The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Open accessAbstract
Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of gram‐negative infections. After several years of clinical use, its popularity diminished because of reports of significant nephrotoxicity and neurotoxicity. Recently, the antibiotic has resurfaced as a last‐line treatment option for multidrug‐resistant organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. The need for antibiotics with coverage of these gram‐negative pathogens is critical because of their high morbidity and mortality, making colistin a very important treatment option. Unfortunately, however, resistance to colistin has been documented among all three of these organisms in case reports. Although the exact mechanism causing colistin resistance has not been defined, it is hypothesized that the PmrA‐PmrB and PhoP‐PhoQ genetic regulatory systems may play a role. Colistin dosages must be optimized, as colistin is a last‐line treatment option; in addition, suboptimal doses have been linked to the development of resistance. The lack of pharmacokinetic and pharmacodynamic studies and no universal harmonization of dose units, however, have made it difficult to derive optimal dosing regimens and specific dosing guidelines for colistin. In critically ill patients who may have multiorgan failure, renal insufficiency may alter colistin pharmacokinetics. Therefore, dosage alterations in this patient population are imperative to achieve maximal efficacy and minimal toxicity. With regard to colistin toxicity, most studies show that nephrotoxicity is reversible and less frequent than once thought, and neurotoxicity is rare. Further research is needed to fully understand the impact that the two regulatory systems have on resistance, as well as the dosages of colistin needed to inhibit and overcome these developing patterns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
Gunn, J. S., Lim, K. B., Krueger, J., Kim, K., Guo, L., Hackett, M., & Miller, S. I. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00757.x · Cited by 655
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Garnacho‐Montero, J., Ortiz‐Leyba, C., Jimenez‐Jimenez, F. J., Barrero‐Almodovar, A. E., Garcia‐Garmendia, J. L., Bernabeu‐WittelI, M., Gallego‐Lara, S. L., & Madrazo‐Osuna, J. (2003) · Clinical Infectious Diseases · doi:10.1086/374337 · Cited by 470
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
McPhee, J. B., Lewenza, S., & Hancock, R. E. W. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03673.x · Cited by 443
Moskowitz, S. M., Ernst, R. K., & Miller, S. I. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.2.575-579.2004 · Cited by 418
Gunn, J. S., & Miller, S. I. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.23.6857-6864.1996 · Cited by 409
Gunn, J. S., Ryan, S. S., van Velkinburgh, J. C., Ernst, R. K., & Miller, S. I. (2000) · Infection and Immunity · doi:10.1128/.68.11.6139-6146.2000 · Cited by 398
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Zhang, L., Dhillon, P., Yan, H., Farmer, S., & Hancock, R. E. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3317-3321.2000 · Cited by 349
Trent, M. S., Ribeiro, A. A., Lin, S., Cotter, R. J., & Raetz, C. R. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106961200 · Cited by 336
Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy
Trotman, R. L., Williamson, J. C., Shoemaker, D. M., & Salzer, W. L. (2005) · Clinical Infectious Diseases · doi:10.1086/444500 · Cited by 292
Regulation of polymyxin resistance and adaptation to low-Mg2+ environments
Groisman, E. A., Kayser, J., & Soncini, F. C. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.22.7040-7045.1997 · Cited by 282
Antoniadou, A., Kontopidou, F., Poulakou, G., Koratzanis, E., Galani, I., Papadomichelakis, E., Kopterides, P., Souli, M., Armaganidis, A., & Giamarellou, H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl562 · Cited by 273
Ko, K. S., Suh, J. Y., Kwon, K. T., Jung, S.-I., Park, K.-H., Kang, C. I., Chung, D. R., Peck, K. R., & Song, J.-H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm305 · Cited by 262
Macfarlane, E. L. A., Kwasnicka, A., Ochs, M. M., & Hancock, R. E. W. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01600.x · Cited by 254
Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Falagas, M. E., Rizos, M., Bliziotis, I. A., Rellos, K., Kasiakou, S. K., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-1 · Cited by 242
McPhee, J. B., Bains, M., Winsor, G., Lewenza, S., Kwasnicka, A., Brazas, M. D., Brinkman, F. S. L., & Hancock, R. E. W. (2006) · Journal of Bacteriology · doi:10.1128/jb.00053-06 · Cited by 225
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria
Falagas, M. E., Bliziotis, I. A., Kasiakou, S. K., Samonis, G., Athanassopoulou, P., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-24 · Cited by 224
Nicas, T. I., & Hancock, R. E. W. (1980) · Journal of Bacteriology · doi:10.1128/jb.143.2.872-878.1980 · Cited by 221
Two-component regulatory systems can interact to process multiple environmental signals
Soncini, F. C., & Groisman, E. A. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.23.6796-6801.1996 · Cited by 209
Macfarlane, E. L. A., Kwasnicka, A., & Hancock, R. E. W. (2000) · Microbiology · doi:10.1099/00221287-146-10-2543 · Cited by 209
Dudhani, R. V., Turnidge, J. D., Coulthard, K., Milne, R. W., Rayner, C. R., Li, J., & Nation, R. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01114-09 · Cited by 205
Markou, N., Markantonis, S. L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., Rafailidis, P., Apostolakos, H., & Baltopoulos, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.01.015 · Cited by 191
Reina, R., Estenssoro, E., Sáenz, G., Canales, H. S., Gonzalvo, R., Vidal, G., Martins, G., Das Neves, A., Santander, O., & Ramos, C. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2691-4 · Cited by 186
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae
Poudyal, A., Howden, B. P., Bell, J. M., Gao, W., Owen, R. J., Turnidge, J. D., Nation, R. L., & Li, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn425 · Cited by 185
Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
Al-Aloul, M., Miller, H., Alapati, S., Stockton, P. A., Ledson, M. J., & Walshaw, M. J. (2005) · Pediatric Pulmonology · doi:10.1002/ppul.20138 · Cited by 178
In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Owen, R. J., Li, J., Nation, R. L., & Spelman, D. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl512 · Cited by 176
Colistin susceptibility testing by Etest and disk diffusion methods
Galani, I., Kontopidou, F., Souli, M., Rekatsina, P.-D., Koratzanis, E., Deliolanis, J., & Giamarellou, H. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.01.011 · Cited by 169
Talbot et al. (2006 42:657-68)
(2006) · Clinical Infectious Diseases · doi:10.1086/503200 · Cited by 166
Acid pH activation of the PmrA/PmrB two‐component regulatory system of Salmonella enterica
Perez, J. C., & Groisman, E. A. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05512.x · Cited by 158
Falagas, M. E., Kasiakou, S. K., Tsiodras, S., & Michalopoulos, A. (2006) · Clinical Medicine & Research · doi:10.3121/cmr.4.2.138 · Cited by 158
Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa
Peterson, A. A., Hancock, R. E. W., & McGroarty, E. J. (1985) · Journal of Bacteriology · doi:10.1128/jb.164.3.1256-1261.1985 · Cited by 156
Yau, W., Owen, R. J., Poudyal, A., Bell, J. M., Turnidge, J. D., Yu, H. H., Nation, R. L., & Li, J. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.11.002 · Cited by 152
Bulitta, J. B., Yang, J. C., Yohonn, L., Ly, N. S., Brown, S. V., D'Hondt, R. E., Jusko, W. J., Forrest, A., & Tsuji, B. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00881-09 · Cited by 152
Self-citationBergen, P. J., Li, J., Nation, R. L., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm511 · Cited by 140
Tan, C.-H., Li, J., & Nation, R. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01571-06 · Cited by 138
Conway, S. P., Pond, M. N., Watson, A., Etherington, C., Robey, H. L., & Goldman, M. H. (1997) · Thorax · doi:10.1136/thx.52.11.987 · Cited by 136
Kwon, D. H., & Lu, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1615-1622.2006 · Cited by 135
Arroyo, L. A. R., García-Curiel, A., Pachón-Ibáñez, M. E., Llanos, A. C., Ruiz, M. T., Pachón, J., & Aznar, J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.903-905.2005 · Cited by 130
Rodríguez, C. H., Bombicino, K. A., Granados, G., Nastro, M., Carlos, V., & Angela, F. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.05.019 · Cited by 116
Susceptibility of Acinetobacter Strains Isolated from Deployed U.S. Military Personnel
Hawley, J. S., Murray, C. K., Griffith, M. E., McElmeel, M. L., Fulcher, L. C., Hospenthal, D. R., & Jorgensen, J. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00858-06 · Cited by 116
Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide
DIXON, R. A., & Chopra, I. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.5.781 · Cited by 112
Extensively Drug-Resistant Acinetobacter baumannii
Doi, Y., Husain, S., Potoski, B. A., McCurry, K. R., & Paterson, D. L. (2009) · Emerging infectious diseases · doi:10.3201/eid1506.081006 · Cited by 99
Kasiakou, S. K., Rafailidis, P. I., Liaropoulos, K., & Falagas, M. E. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.05.008 · Cited by 70
Suh, J.-Y., Son, J. S., Chung, D. R., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00762-09 · Cited by 70
Schülin, T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.403 · Cited by 70
Soon, R. L., Nation, R. L., Hartley, P. G., Larson, I. C., & Li, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00497-09 · Cited by 65
Nicas, T. I., & Hancock, R. E. W. (1983) · Microbiology · doi:10.1099/00221287-129-2-509 · Cited by 60
Cited by
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Olaitan, A. O., Morand, S., & Rolain, J.-M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00643 · Cited by 1,395
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationColistin and its role in the Era of antibiotic resistance: an extended review (2000–2019)
El-Sayed Ahmed, M. A. E.-G., Zhong, L.-L., Shen, C., Yang, Y., Doi, Y., & Tian, G.-B. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1754133 · Cited by 761
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications
Chen, C. H., & Lu, T. K. (2020) · Antibiotics · doi:10.3390/antibiotics9010024 · Cited by 598
Metadata
- Authors
- Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2010-12
- Volume
- 30
- Issue
- 12
- Pages
- 1279-1291
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2145705966
- Cited by
- 444
- References
- 56
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.